Диагностическая и интервенционная радиология. №3 2014

Гепарин-индуцированная тромбоцитопения в кардиохирургии

*А.Л. Пирогов – д.м.н. С.А. Пискунов – врач

ФГБУ «Федеральный центр сердечно-сосудистой хирургии» Минздрава РФ, г. Челябинск 454003, Россия, г. Челябинск, пр-т Героя России Е.Н. Родионова, 2

Стр. 87-93

0 просмотров

Опубликовано: 1 марта 2014

Аннотация / Abstract

Резюме: В обзоре предоставлены данные литературы о гепарин-индуцированной тромбоцитопении, её формах, патогенезе развития состояния и её клинических проявлениях. Рассмотрены варианты лечения этого осложнения и положения рекомендаций Американской коллегии врачей специалистов по заболеваниям органов грудной клетки (АССР), принятые на IX Конференции по антитромботической терапии и профилактике тромбозов в 2012 году. Ключевые слова: • гепарин-индуцированная тромбоцитопения (ГИТ) • кардиохирургия • лечение • профилактика Heparin induced thrombocytopenia in cardiac surgery *Pirogov A.L. – MD, PhD Piskunov S.A. – MD Federal Center of Cardiovascular surgery 2, ulitsa Geroya Rossii Evgeniya Rodionova, Chelyabinsk, Russian Federation 454003 ABSTRACT: The review presents literature data on the heparin-induced thrombocytopenia, its forms, the pathogenesis of condition and its clinical manifestations. Consideration of options for treatment of this complication and provisions recommendations of the American College of specialist doctors in diseases of the chest (ACCP), adopted at the IX Conference on antithrombotic therapy and prevention of thrombosis in 2012. KEY-WORDS • heparin-induced thrombocytopenia (HIT) • сardiovascular surgery • treatment • prophylaxis В ближайшие годы исполнится 100 лет с момента открытия J. McLean в 1916 году вещества, названного гепарином – прямого антикоагулянта, основное уникальное свойство которого состоит в предотвращении тромбозов, и реализуется через активацию антитромбина III. Практически во всех случаях сердечно-сосудистого вмешательства, будь то: стентирование, операция, выполняемая с использованием искусственного кровообращения, радиочастотная абляция или ангиография, а также предоперационная подготовка или постоперационное ведение пациента – используется гепарин. Но, в середине прошлого века при широком использовании этого п...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Kelton J.G., Warkentin T.E. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008; 112 (7): 2607–16.
2. Weismann R.E., Tobin R.W. Arterial embolism occurring during systemic heparin therapy. AMA Arch. Surg. 1958; 76 (2): 219–25; discussion 225–7.
3. Natelson E.A., Lynch E.C., Alfrey C.P., Gross J.B. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann. Intern. Med. 1969; 71 (6): 1121–5.
4. Rhodes G.R., Dixon R.H., Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. Gynecol. Obstet. 1973; 136 (3): 409–16.
5. Jang I.K., Hursting M.J. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005; 111 (20): 2671–83.
6. Greinacher A., Warkentin T.E. Heparin-induced thrombocytopenia. New York, N.Y: Marcel Dekker, 2004; 627 р.
7. Prechel М.М., Walenga М.J. Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia. Thrombosis Journal. 2013; 11:7.
8. Martel N., Lee J., Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106 (8): 2710–15.
9. Warkentin T.E., Greinacher A. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest. 2007; 132 (4): 1108–10.
10. Warkentin T.E., Sheppard J.A., Sigouin C.S., et al. Gender imbalance and risk factor interaction in heparin-induced thrombocytopenia. Blood. 2006; 108 (9): 2937-41.
11. Brieger D.B., Mak K.H., Kottke-Marchant K., Topol E.J. Heparin-induced thrombocytopenia. J. Am. Coll. Cardiol. 1998; 31 (7): 1449–59.
12. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb. J. 2005; 3: 14.
13. Warkentin T.E., Kelton J.G.. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann. Intern. Med. 2001; 135 (7): 502–6.
14. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 2001; 344 (17): 1286–92.
15. Greinacher A., Pötzsch B., Amiral J., Dummel V., Eichner A., Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb. Haemost. 1994; 71 (2): 247–51.
16. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 1996; 101 (5): 502–7.
17. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (6 Suppl.): 340–80.
18. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol. 2003; 121 (4): 535–55.
19. Linkins L., Dans A.L., Moores L.K., et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis,
9th edition: American College of Chest Physicians evidence-based clinical practice Guidelines. Chest. 2012; 141 (2 suppl.): 495–530.
20. Warkentin T.E., Roberts T.S., Hirsch J., Kelton J.G. Heparininduced skin lesions and other unusual sequelae of the heparininduced-thrombocytopenia syndrome: a nested cohort study. Chest. 2005; 127 (5): 1857–61.
21. Bleasel J.F., Rasko J.E., Rickard K.A., Richards G. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med. J. Aust. 1992; 157 (3): 192–3.
22. Greinacher A., Juhl D., Strobel U. et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J. Thromb. Haemost. 2007; 5 (8): 1666–73.
23. Warkentin T.E., Sheppard J.A.Testing for heparin-induced thrombocytopenia antibodies. Transfus. Med. Rev. 2006; 20 (4): 259–72.
24. Tomer A., Masalunga C., Abshire T.C. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am. J. Hematol. 1999; 61 (1): 53–61.
25. Meyer O., Salama A., Pittet N., Schwind P. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet. 1999; 354 (9189): 1525–6.
26. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 Suppl.): 311–337.
27. Greinacher A., Lubenow N., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003; 108 (17): 2062–5.
28. Lewis B.E., Matthai W.H., Cohen M., Moses J.W., Hursting M.J., Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc. Interv. 2002; 57 (2): 177–84.
29. Campbell K.R., Mahaffey K.W., Lewis B.E. et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J. Invasive Cardiol. 2000; 12 Suppl. F: 14F–9.
30. Warkentin T.E., Cook R.J., Marder V.J. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106 (12): 3791–6.
31. Walenga J.M., Prechel M., Jeske W.P. et al. Rivaroxaban an oral, direct Factor Xa inhibitor has potential for the management of patients with heparin-induced thrombocytopenia. Br. J. Haematol. 2008; 143 (1): 92–9.
32. Shantsila E., Lip G.Y., Chong B.H. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest. 2009; 135 (6): 1651–64.
33. Бокерия Л.А., Чигерин И.Н. Гепарининдуцированная тромбоцитопения (современное состояние проблемы). М. Изд. НЦССХ им. А.Н. Бакулева. 2007; 96 с.Bokerija L.A., Chigerin I.N. Geparininducirovannaja trombocitopenija (sovremennoe sostojanie problemy) [Heparin-induced thrombocitopenia (modern condition of problem)]. M. Izd. NCSSH im. A.N. Bakuleva. 2007; 96 s [In Russ].
34. Pötzsch B., Klövekorn W.P., Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 2000; 343 (7): 515.
35. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann. Thorac. Surg. 2003; 76 (6): 2121–31.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Гепарин-индуцированная тромбоцитопения в кардиохирургии

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Гепарин-индуцированная тромбоцитопения в кардиохирургии

Материал для специалистов

Con-Med Passport